Equities research analysts expect Ocular Therapeutix Inc (NASDAQ:OCUL) to post $1.00 million in sales for the current quarter, according to Zacks. Three analysts have made estimates for Ocular Therapeutix’s earnings. The highest sales estimate is $2.00 million and the lowest is $500,000.00. Ocular Therapeutix reported sales of $650,000.00 in the same quarter last year, which indicates a positive year-over-year growth rate of 53.8%. The company is expected to issue its next quarterly earnings results on Tuesday, August 6th.

On average, analysts expect that Ocular Therapeutix will report full-year sales of $12.72 million for the current financial year, with estimates ranging from $9.18 million to $15.00 million. For the next year, analysts expect that the firm will report sales of $56.10 million, with estimates ranging from $26.27 million to $72.03 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side analysts that that provide coverage for Ocular Therapeutix.

Ocular Therapeutix (NASDAQ:OCUL) last posted its earnings results on Friday, May 10th. The biopharmaceutical company reported ($0.45) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.42) by ($0.03). Ocular Therapeutix had a negative net margin of 2,956.91% and a negative return on equity of 165.85%. The company had revenue of $0.49 million during the quarter, compared to the consensus estimate of $0.45 million.

OCUL has been the topic of a number of recent analyst reports. Piper Jaffray Companies dropped their price target on Ocular Therapeutix to $8.00 and set a “market perform” rating on the stock in a report on Monday, May 20th. HC Wainwright dropped their price target on Ocular Therapeutix from $12.00 to $9.00 and set a “buy” rating on the stock in a report on Tuesday, May 21st. Zacks Investment Research lowered Ocular Therapeutix from a “hold” rating to a “sell” rating in a report on Tuesday, March 5th. Cowen lowered Ocular Therapeutix from an “outperform” rating to a “market perform” rating and dropped their price target for the stock from $13.00 to $3.00 in a report on Tuesday, May 21st. Finally, ValuEngine lowered Ocular Therapeutix from a “hold” rating to a “sell” rating in a report on Wednesday, May 1st. One analyst has rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $9.18.

Shares of OCUL stock traded down $0.01 during trading hours on Wednesday, reaching $4.36. The company had a trading volume of 17,764 shares, compared to its average volume of 1,093,917. Ocular Therapeutix has a 12 month low of $2.35 and a 12 month high of $8.24. The company has a current ratio of 9.19, a quick ratio of 9.16 and a debt-to-equity ratio of 2.17. The firm has a fifty day moving average of $3.35. The company has a market capitalization of $184.64 million, a P/E ratio of -2.83 and a beta of 1.91.

In other news, Chairman Amarpreet Sawhney bought 45,780 shares of the stock in a transaction on Wednesday, June 5th. The shares were purchased at an average cost of $2.91 per share, for a total transaction of $133,219.80. Following the completion of the purchase, the chairman now directly owns 898,711 shares in the company, valued at approximately $2,615,249.01. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Antony C. Mattessich bought 40,000 shares of the stock in a transaction on Thursday, June 6th. The stock was purchased at an average price of $2.81 per share, for a total transaction of $112,400.00. Following the completion of the purchase, the chief executive officer now owns 97,900 shares of the company’s stock, valued at $275,099. The disclosure for this purchase can be found here. Insiders have purchased 222,248 shares of company stock worth $639,186 over the last quarter. 16.10% of the stock is currently owned by corporate insiders.

Institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. raised its stake in shares of Ocular Therapeutix by 6.9% in the third quarter. Vanguard Group Inc. now owns 1,427,533 shares of the biopharmaceutical company’s stock valued at $9,821,000 after buying an additional 92,335 shares during the period. Deltec Asset Management LLC raised its stake in shares of Ocular Therapeutix by 13.8% in the first quarter. Deltec Asset Management LLC now owns 824,747 shares of the biopharmaceutical company’s stock valued at $3,274,000 after buying an additional 100,000 shares during the period. Geode Capital Management LLC raised its stake in shares of Ocular Therapeutix by 15.2% in the fourth quarter. Geode Capital Management LLC now owns 350,673 shares of the biopharmaceutical company’s stock valued at $1,395,000 after buying an additional 46,281 shares during the period. Two Sigma Investments LP raised its stake in shares of Ocular Therapeutix by 269.5% in the fourth quarter. Two Sigma Investments LP now owns 70,181 shares of the biopharmaceutical company’s stock valued at $279,000 after buying an additional 51,186 shares during the period. Finally, Summer Road LLC raised its stake in shares of Ocular Therapeutix by 25.0% in the fourth quarter. Summer Road LLC now owns 3,784,850 shares of the biopharmaceutical company’s stock valued at $15,064,000 after buying an additional 757,362 shares during the period. Hedge funds and other institutional investors own 52.33% of the company’s stock.

About Ocular Therapeutix

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. The company markets ReSure Sealant, a hydrogel ophthalmic wound sealant to seal corneal incisions following cataract surgery.

Further Reading: How Do Mutual Funds Work?

Get a free copy of the Zacks research report on Ocular Therapeutix (OCUL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Ocular Therapeutix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix and related companies with MarketBeat.com's FREE daily email newsletter.